Richmond Times-Dispatch4d
Petersburg drugmaker Civica misses target for selling cheap insulin
The plant will make three types of insulin, which Civica has pledged to sell for $30 a vial and $55 for a box of five pens.
FiercePharma1mon
FDA signs off on Sanofi's insulin biosimilar, the first for Novo Nordisk's rapid-acting NovoLog
More than three years after approving two biosimilars referencing Sanofi’s long-acting insulin Lantus, the FDA has ... dose or in a multiple-dose 10 mL vial. It is for adults and pediatric ...
pharmaphorum2d
Civica plans shake-up of insulin sector with low-cost biosimilars
The biosimilars – which will be interchangeable with Sanofi's Lantus (insulin glargine ... prices of the originator insulin are around $329 per vial and $510 for five pens, according to ...
pharmaphorum5d
Sanofi turns the tables on Lilly with biosimilar fast-acting insulin
But it looks unlikely that Lilly will be able to maintain this with the launch of Humalog, which is available in vial ... acting insulin market with a cheaper version of Sanofi’s Lantus (insulin ...
What consumers should know about the FTC’s upcoming lawsuit against CVS over how it negotiates drug prices
A vial of insulin costs about $8 to manufacture, researchers estimate. But Sanofi’s Lantus costs $292 per vial, Nordisk’s ...
Medscape1d
Room-temperature Storage of Medications Labeled for Refrigeration
28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% insulin aspart protamine suspension ...
Benzinga.com1mon
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Merilog is available in a 3 mL prefilled pen and a 10 mL vial, joining two long-acting ... to lower the price of its best-selling insulin product, Lantus (insulin glargine), by 78%.